Brief: Aurobindo Pharma Says Curateq Biologics Receives Approval For Biosimilar Dyrupeg
24/06/2025 14:03
June 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA - CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR DYRUPEG FROM UK’S MHRA Source text: [ID:] Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11